A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis

Clinical trial NCT00441103 · COMPLETED

Trial details

NCT number: NCT00441103
Sponsor: Merck KGaA, Darmstadt, Germany
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Multiple Sclerosis, Relapsing-Remitting

Start date: 2006-12-01
Primary completion: 2008-11-01
Enrollment: 180

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.